Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Total Liabilities (2016 - 2025)

Guided Therapeutics' Total Liabilities history spans 16 years, with the latest figure at $6.5 million for Q3 2025.

  • For Q3 2025, Total Liabilities rose 6.19% year-over-year to $6.5 million; the TTM value through Sep 2025 reached $6.5 million, up 6.19%, while the annual FY2024 figure was $6.3 million, 14.47% up from the prior year.
  • Total Liabilities for Q3 2025 was $6.5 million at Guided Therapeutics, up from $6.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $10.3 million in Q1 2021 and bottomed at $5.5 million in Q4 2023.
  • The 5-year median for Total Liabilities is $6.3 million (2024), against an average of $6.5 million.
  • The largest annual shift saw Total Liabilities tumbled 57.44% in 2021 before it increased 14.47% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $7.5 million in 2021, then dropped by 16.51% to $6.2 million in 2022, then fell by 12.39% to $5.5 million in 2023, then increased by 14.47% to $6.3 million in 2024, then increased by 4.5% to $6.5 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Total Liabilities are $6.5 million (Q3 2025), $6.4 million (Q2 2025), and $6.0 million (Q1 2025).